Benefit of tianeptine and morphine in a transgenic model of familial amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 7, Issue 1, 2006, Pages 32-37

  Chritin, Muriel ^a   Savasta, Marc ^b   Besson, Gerard ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Amyotrophic lateral sclerosis; Animal model; Morphine; Tianeptine

Indexed keywords

MORPHINE; TIANEPTINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, TRANSGENIC; MORPHINE; RECOVERY OF FUNCTION; SUPEROXIDE DISMUTASE; SURVIVAL RATE; THIAZEPINES; TREATMENT OUTCOME;

EID: 33645111698     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820510012022     Document Type: Article

References (41)

1. Deng, H. X. and Hentati, A. and Tainer, J. A. and Iqbal, Z. and Cayabyab, A. and Hung, W. Y. and et al. (1993) Amyotrophic lateral sclerosis and structural defects in Cu/Zn superoxide dismutase. Science, pp. 261:1047 - 50.
2. Rosen, D. R. and Siddique, T. and Patterson, D. and Figlewicz, D. A. and Sapp, P. and Hentati, A. and et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362, pp. 59 - 62.
3. Price D.L., Wong P.C. Becher M.W. et al. 1998 Familial amyotrophic lateral sclerosis and transgenic models Neurosci News 1 21-27
4. Gurney, M. E. and Pu, H. and Chiu, A. Y. and Dal Canto, M. C. and Polchow, C. Y. and Alexander, D. D. and Caliendo, J. and et al. (1994) Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science, 264, pp. 1772 - 5.
5. Dal Canto, M. C. and Gurney, M. E. (199) Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu/Zn SOD, and in mice overexpressing wild-type human SOD: A model of familial lateral sclerosis. Brain Res, 676, pp. 25 - 40.
6. Puig, S. and Rivot, J. P. and Besson, J. M. (1993) Effects of tianeptine on 5-hydroxyindoles and on the morphine-induced increase in 5-HT metabolism at the medullary dorsal horn level as measured by in vivo voltametry in freely moving rats. Brain Res, 600, pp. 219 - 24.
7. Aanonsen, L. M. and Wilcox, G. L. (1987) Nociceptive action of excitatory amino acids in the mouse: Effects of spinally administered opioids, phencyclidine and sigma agonists. J.Pharmacol Exp Ther, 243, pp. 9 - 19.
8. Wilde, M. I. and Benfield, P. (1995) Tianeptine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs, 49, pp. 411 - 39.
9. Fattaccini, C. M. and Bolanos-Jimenez, F. and Gozlan, H. and Hamon, M. (1990) Tianeptine stimulates uptake of 5-hydroxytryptamine in vivo in the rat brain. Neuropharmacology, 29, pp. 1 - 8.
10. Ortiz, J. and Mocaer, E. and Artigas, F. (1991) Effects of the antidepressant drug tianeptine on plasma and platelet serotonin concentrations in the rat. Eur J Pharmacol, 199, pp. 335 - 9.
11. Chamba, G. and Lemoine, P. and Flachaire, E. and Ferry, N. and Quincy, C. and Sassard, J. and et al. (1991) Increased serotonin platelet uptake after tianeptine administration in depressed patients. Biol Psychiat, 30, pp. 609 - 17.
12. Frankfurt, M. and McKittrick, C. R. and McEwen, B. S. and Luine, V. N. (1995) Tianeptine treatment induces regionally specific changes in monoamines. Brain Res, 696, pp. 1 - 6.
13. Kato, G. and Weitch, A. F. (1988) Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol, 11, pp. 43 - 50.
14. Bensimon, G. and Lacomblez, L. and Meininger, V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med, 330, pp. 585 - 591.
15. Lacomblez, L. and Bensimon, G. and Leigh, P. N. and Meininger, V. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. ALS/ Riluzole Study Group II. Lancet, 347, pp. 1425 - 31.
16. Chritin, M. and Besson, G. and Mallaret, M. and Savasta, M. (2001) Sclérose latérale amyotrophique et modèles animaux. Rev Neurol, 157, pp. 1351 - 61.
17. Bruijn, L. I. and Cleveland, D. W. (1996) Mechanisms of selective motor neuron death in ALS: Insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol, 22, pp. 373 - 87.
18. Tu, P. H. and Gurney, M. E. and Julien, J. P. and Lee, V. M. and Trojanowski, J. Q. and et al. (1997) Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor disease. Lab Invest, 76, pp. 441 - 5.
19. Gurney, M. E. and Cutting, F. B. and Zhai, P. and et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial lateral sclerosis. Ann Neurol, 39, pp. 147 - 57.
20. Gurney, M. E. and Fleck, T. J. and Himes, C. S. and Hall, E. D. (1998) Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology, 50, pp. 62 - 6.
21. Hottinger, A. F. and Fine, E. G. and Gurney, M. E. and Zurn, A. D. and Aebischer, P. and et al. (1997) The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci, 9, pp. 1548 - 51.
22. Nagano, S. and Ogawa, Y. and Yanagihara, T. and Sakoda, S. (1999) Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett, 265, pp. 159 - 62.
23. Barneoud, P. and Curet, O. (1999) Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol, 155, pp. 243 - 51.
24. Benoit, E. and Escande, D. (1991) Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch, 419, pp. 603 - 9.
25. Martin, D. and Thompson, M. A. and Nadler, J. V. (1993) The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol, 250, pp. 473 - 6.
26. Hebert, T. and Drapeau, P. and Pradier, L. and Dunn, R. J. (1994) Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol, 45, pp. 1055 - 60.
27. Malgouris, C. and Daniel, M. and Doble, A. (1994) Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett, 177, pp. 95 - 9.
28. Uzbay, I. T. and Cinar, M. G. and Aytemir, M. and Tuglular, I. (1999) Analgesic effect of tianeptine in mice. Life Sci, 64, pp. 1313 - 9.
29. Bowker, R. M. and Westlund, K. N. and Sullivan, M. C. and Coutler, J. D. (1982) Organization of descending serotoninergic projections to the spinal cord. Prog Brain Res, 57, pp. 239 - 98.
30. Marlier, L. and Teilhac, J. R. and Cerruti, C. and Privat, A. (1991) Autoradiographic mapping of 5-HT1, 5-HT1A, 5-HT1B and 5-HT2 receptors in the rat spinal cord. Brain Res, 550, pp. 15 - 23.
31. Dziedzick-Wasylewska, M. and Rogoz, Z. and Skuza, G. and Dlaboga, D. and Maj, J. and (2002) Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D2/D3 receptors. Behav Pharmacol, 13, pp. 127 - 38.
32. Chen, L. and Huang, L.- Y. M. (1991) Sustained potentiation of NMDA receptor-mediated glutamate response through activation of protein kinase C by a μ opioid. Neuron, 7, pp. 319 - 26.
33. Elmer, G. I. and Evans, J. L. and Ladenheim, B. and Epstein, C. J. and Cadet, J. L. and (1995) Transgenic superoxide dismutase mice differ in opioid-induced analgesia. Eur J Pharmacol, 283, pp. 227 - 32.
34. Marzullo, G. and Hine, B. (1980) Opiate receptor function may be modulated through an oxidation-reduction mechanism. Science, 283, pp. 227 - 32.
35. Vezina, P. and Stewart, J. (1989) The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Res, 499, pp. 108 - 20.
36. Murphy, N. P. and Lam, H. A. and Maidment, N. T. (2001) A comparison of morphine-induced locomotor and mesolimbic dopamine release in C57BL6, 129Sv and DBA2 mice. J Neurochem, 79, pp. 626 - 35.
37. Woo, S. H. and Kim, H. S. (2001) Inhibition of diazepam on morphine-induced hyperactivity, reverse tolerance and post-synaptic dopamine receptor supersensitivity. Pharmacol Res, 44, pp. 467 - 72.
38. Del Rosario, C. N. and Pacchioni, A. M. and Cancela, L. M. (2002) Influence of acute and repeated restraint stress on morphine-induced locomotion: Involvement of dopamine, opioid and glutamate receptors. Behav Brain Res, 134, pp. 229 - 38.
39. Drouin, C. and Darracq, L. and Trovero, F. and Blanc, G. and Glowinski, J. and Cotecchia, S. and Tassin, J. P. and (2002) Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci, 22, pp. 2873 - 84.
40. Airio, J. and Ahtee, L. (1999) The involvement of noradrenergic transmission in the morphine-induced locomotor hyperactivity in mice withdrawn from repeated morphine treatment. Br J Pharmacol, 126, pp. 1609 - 19.
41. Handal, M. and Grung, M. and Skurtveit, S. and Ripel, A. and Morland, J. and (2002) Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. Pharmacol Biochem Behav, 73, pp. 883 - 92.